Sandoz, a division of Novartis, has finalized a $275 million settlement in an antitrust class-action lawsuit regarding generic drugs, expected to be paid by the end of 2024. Additionally, the company has reserved $265 million for potential claims from plaintiffs who opted out of the litigation, signaling a proactive approach to future legal costs. This resolution is anticipated to enhance investor confidence and allow Sandoz to focus on operational efficiency and innovation in the growing generic pharmaceuticals market.